CA2467433A1 - Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer - Google Patents

Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer Download PDF

Info

Publication number: CA2467433A1
Authority: CA; Canada
Prior art keywords: cancer; protein; sequence; nucleic acid; cell
Prior art date: 2001-11-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA002467433A

Other languages

English (en)

French (fr)

Inventor

Daniel Afar

Natasha Aziz

Wendy M. Ginsburg

Kurt C. Gish

Richard Glynne

Peter A. Hevezi

David H. Mack

Richard Murray

Susan R. Watson

Keith E. Wilson

Albert Zlotnik

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

EOS Biotechnology Inc

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-13

Filing date

2002-11-13

Publication date

2003-05-22

2002-11-13 Application filed by Individual filed Critical Individual

2002-11-13 Priority claimed from PCT/US2002/036810 external-priority patent/WO2003042661A2/en

2003-05-22 Publication of CA2467433A1 publication Critical patent/CA2467433A1/en

Status Abandoned legal-status Critical Current

Links

206010028980 Neoplasm Diseases 0.000 title claims abstract description 539
238000000034 method Methods 0.000 title claims abstract description 176
201000011510 cancer Diseases 0.000 title claims description 476
239000000203 mixture Substances 0.000 title abstract description 43
238000003745 diagnosis Methods 0.000 title abstract description 21
238000012216 screening Methods 0.000 title description 31
108090000623 proteins and genes Proteins 0.000 claims abstract description 478
230000014509 gene expression Effects 0.000 claims abstract description 143
238000011282 treatment Methods 0.000 claims abstract description 30
102000004169 proteins and genes Human genes 0.000 claims description 366
150000007523 nucleic acids Chemical class 0.000 claims description 224
102000039446 nucleic acids Human genes 0.000 claims description 198
108020004707 nucleic acids Proteins 0.000 claims description 198
108090000765 processed proteins & peptides Proteins 0.000 claims description 149
102000004196 processed proteins & peptides Human genes 0.000 claims description 124
229920001184 polypeptide Polymers 0.000 claims description 105
239000000523 sample Substances 0.000 claims description 89
150000001875 compounds Chemical class 0.000 claims description 85
230000000694 effects Effects 0.000 claims description 65
238000012360 testing method Methods 0.000 claims description 38
102000040430 polynucleotide Human genes 0.000 claims description 36
108091033319 polynucleotide Proteins 0.000 claims description 36
239000002157 polynucleotide Substances 0.000 claims description 36
239000013604 expression vector Substances 0.000 claims description 35
239000000126 substance Substances 0.000 claims description 34
108020004999 messenger RNA Proteins 0.000 claims description 27
238000000018 DNA microarray Methods 0.000 claims description 20
241000124008 Mammalia Species 0.000 claims description 20
108020004711 Nucleic Acid Probes Proteins 0.000 claims description 20
239000002853 nucleic acid probe Substances 0.000 claims description 20
239000012472 biological sample Substances 0.000 claims description 18
230000007170 pathology Effects 0.000 claims description 17
239000012636 effector Substances 0.000 claims description 12
230000001575 pathological effect Effects 0.000 claims description 12
210000002966 serum Anatomy 0.000 claims description 12
210000004369 blood Anatomy 0.000 claims description 10
239000008280 blood Substances 0.000 claims description 10
210000000056 organ Anatomy 0.000 claims description 9
239000007850 fluorescent dye Substances 0.000 claims description 8
108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 7
102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
230000008685 targeting Effects 0.000 claims description 6
238000007878 drug screening assay Methods 0.000 claims description 4
231100000433 cytotoxic Toxicity 0.000 claims description 3
230000001472 cytotoxic effect Effects 0.000 claims description 3
238000011285 therapeutic regimen Methods 0.000 claims description 2
210000002700 urine Anatomy 0.000 claims description 2
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 55
201000010099 disease Diseases 0.000 abstract description 47
230000001105 regulatory effect Effects 0.000 abstract description 20
238000004393 prognosis Methods 0.000 abstract description 14
235000018102 proteins Nutrition 0.000 description 351
210000004027 cell Anatomy 0.000 description 211
230000027455 binding Effects 0.000 description 82
238000009739 binding Methods 0.000 description 80
210000001519 tissue Anatomy 0.000 description 75
238000003556 assay Methods 0.000 description 65
239000003795 chemical substances by application Substances 0.000 description 53
235000001014 amino acid Nutrition 0.000 description 50
229940024606 amino acid Drugs 0.000 description 44
150000001413 amino acids Chemical class 0.000 description 44
102000048850 Neoplasm Genes Human genes 0.000 description 39
108700019961 Neoplasm Genes Proteins 0.000 description 39
238000009396 hybridization Methods 0.000 description 36
125000003729 nucleotide group Chemical group 0.000 description 36
239000002773 nucleotide Substances 0.000 description 35
125000003275 alpha amino acid group Chemical group 0.000 description 34
241000282414 Homo sapiens Species 0.000 description 33
-1 antibodies Chemical class 0.000 description 32
239000012634 fragment Substances 0.000 description 30
230000000692 anti-sense effect Effects 0.000 description 29
230000001225 therapeutic effect Effects 0.000 description 27
108020004414 DNA Proteins 0.000 description 25
238000003752 polymerase chain reaction Methods 0.000 description 25
239000013598 vector Substances 0.000 description 25
239000000427 antigen Substances 0.000 description 24
102000036639 antigens Human genes 0.000 description 24
108091007433 antigens Proteins 0.000 description 24
239000003814 drug Substances 0.000 description 24
239000000047 product Substances 0.000 description 23
239000007787 solid Substances 0.000 description 21
108091028043 Nucleic acid sequence Proteins 0.000 description 20
239000003153 chemical reaction reagent Substances 0.000 description 20
238000006467 substitution reaction Methods 0.000 description 20
230000003834 intracellular effect Effects 0.000 description 19
108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
230000012010 growth Effects 0.000 description 18
230000000295 complement effect Effects 0.000 description 17
239000003446 ligand Substances 0.000 description 17
235000002639 sodium chloride Nutrition 0.000 description 17
229960005486 vaccine Drugs 0.000 description 17
108091034117 Oligonucleotide Proteins 0.000 description 16
239000002671 adjuvant Substances 0.000 description 16
238000004458 analytical method Methods 0.000 description 16
238000004422 calculation algorithm Methods 0.000 description 16
238000001514 detection method Methods 0.000 description 16
238000013518 transcription Methods 0.000 description 16
230000035897 transcription Effects 0.000 description 16
238000000338 in vitro Methods 0.000 description 15
150000003839 salts Chemical class 0.000 description 15
239000000758 substrate Substances 0.000 description 15
108091005461 Nucleic proteins Proteins 0.000 description 14
239000002253 acid Substances 0.000 description 14
230000003321 amplification Effects 0.000 description 14
229940079593 drug Drugs 0.000 description 14
230000006870 function Effects 0.000 description 14
239000003112 inhibitor Substances 0.000 description 14
239000000463 material Substances 0.000 description 14
238000003199 nucleic acid amplification method Methods 0.000 description 14
108090000994 Catalytic RNA Proteins 0.000 description 13
102000053642 Catalytic RNA Human genes 0.000 description 13
108060003951 Immunoglobulin Proteins 0.000 description 13
230000015572 biosynthetic process Effects 0.000 description 13
230000000875 corresponding effect Effects 0.000 description 13
238000013537 high throughput screening Methods 0.000 description 13
102000018358 immunoglobulin Human genes 0.000 description 13
230000003211 malignant effect Effects 0.000 description 13
108091092562 ribozyme Proteins 0.000 description 13
102000035160 transmembrane proteins Human genes 0.000 description 13
108091005703 transmembrane proteins Proteins 0.000 description 13
108020004705 Codon Proteins 0.000 description 12
241001465754 Metazoa Species 0.000 description 12
241000699666 Mus <mouse, genus> Species 0.000 description 12
238000013459 approach Methods 0.000 description 12
238000005516 engineering process Methods 0.000 description 12
239000003102 growth factor Substances 0.000 description 12
102000005962 receptors Human genes 0.000 description 12
238000007792 addition Methods 0.000 description 11
230000008859 change Effects 0.000 description 11
230000007423 decrease Effects 0.000 description 11
238000001727 in vivo Methods 0.000 description 11
230000001965 increasing effect Effects 0.000 description 11
108020003175 receptors Proteins 0.000 description 11
YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 10
108091026890 Coding region Proteins 0.000 description 10
108091093037 Peptide nucleic acid Proteins 0.000 description 10
239000012190 activator Substances 0.000 description 10
150000001720 carbohydrates Chemical class 0.000 description 10
230000001413 cellular effect Effects 0.000 description 10
238000006243 chemical reaction Methods 0.000 description 10
238000001415 gene therapy Methods 0.000 description 10
230000004048 modification Effects 0.000 description 10
238000012986 modification Methods 0.000 description 10
239000003053 toxin Substances 0.000 description 10
201000009030 Carcinoma Diseases 0.000 description 9
102000004190 Enzymes Human genes 0.000 description 9
108090000790 Enzymes Proteins 0.000 description 9
241000699670 Mus sp. Species 0.000 description 9
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 9
230000001580 bacterial effect Effects 0.000 description 9
229940088598 enzyme Drugs 0.000 description 9
230000013595 glycosylation Effects 0.000 description 9
238000006206 glycosylation reaction Methods 0.000 description 9
230000002401 inhibitory effect Effects 0.000 description 9
210000004072 lung Anatomy 0.000 description 9
239000002777 nucleoside Substances 0.000 description 9
150000003384 small molecules Chemical class 0.000 description 9
231100000765 toxin Toxicity 0.000 description 9
108700012359 toxins Proteins 0.000 description 9
108010041986 DNA Vaccines Proteins 0.000 description 8
229940021995 DNA vaccine Drugs 0.000 description 8
ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 8
108010090804 Streptavidin Proteins 0.000 description 8
239000002246 antineoplastic agent Substances 0.000 description 8
238000003491 array Methods 0.000 description 8
238000012217 deletion Methods 0.000 description 8
230000037430 deletion Effects 0.000 description 8
230000002255 enzymatic effect Effects 0.000 description 8
238000011156 evaluation Methods 0.000 description 8
238000003780 insertion Methods 0.000 description 8
230000037431 insertion Effects 0.000 description 8
238000012544 monitoring process Methods 0.000 description 8
238000011002 quantification Methods 0.000 description 8
241000894007 species Species 0.000 description 8
238000003786 synthesis reaction Methods 0.000 description 8
230000004614 tumor growth Effects 0.000 description 8
238000005406 washing Methods 0.000 description 8
206010025323 Lymphomas Diseases 0.000 description 7
206010027476 Metastases Diseases 0.000 description 7
150000007513 acids Chemical class 0.000 description 7
208000009956 adenocarcinoma Diseases 0.000 description 7
230000004075 alteration Effects 0.000 description 7
230000004071 biological effect Effects 0.000 description 7
230000010261 cell growth Effects 0.000 description 7
230000001684 chronic effect Effects 0.000 description 7
229940127089 cytotoxic agent Drugs 0.000 description 7
229940000406 drug candidate Drugs 0.000 description 7
230000028993 immune response Effects 0.000 description 7
229940124452 immunizing agent Drugs 0.000 description 7
238000011534 incubation Methods 0.000 description 7
230000001939 inductive effect Effects 0.000 description 7
125000005647 linker group Chemical group 0.000 description 7
239000002502 liposome Substances 0.000 description 7
239000003550 marker Substances 0.000 description 7
229920000642 polymer Polymers 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
238000000746 purification Methods 0.000 description 7
238000011160 research Methods 0.000 description 7
230000009466 transformation Effects 0.000 description 7
229920001817 Agar Polymers 0.000 description 6
241000894006 Bacteria Species 0.000 description 6
206010006187 Breast cancer Diseases 0.000 description 6
241000238631 Hexapoda Species 0.000 description 6
108091030071 RNAI Proteins 0.000 description 6
241000700159 Rattus Species 0.000 description 6
241000283984 Rodentia Species 0.000 description 6
240000004808 Saccharomyces cerevisiae Species 0.000 description 6
235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 6
230000004913 activation Effects 0.000 description 6
239000008272 agar Substances 0.000 description 6
125000000539 amino acid group Chemical group 0.000 description 6
125000003277 amino group Chemical group 0.000 description 6
238000011161 development Methods 0.000 description 6
230000018109 developmental process Effects 0.000 description 6
208000035475 disorder Diseases 0.000 description 6
125000000524 functional group Chemical group 0.000 description 6
230000004927 fusion Effects 0.000 description 6
239000000499 gel Substances 0.000 description 6
230000009368 gene silencing by RNA Effects 0.000 description 6
230000002068 genetic effect Effects 0.000 description 6
238000003018 immunoassay Methods 0.000 description 6
230000002163 immunogen Effects 0.000 description 6
230000003993 interaction Effects 0.000 description 6
210000004962 mammalian cell Anatomy 0.000 description 6
108010082117 matrigel Proteins 0.000 description 6
230000001404 mediated effect Effects 0.000 description 6
230000009401 metastasis Effects 0.000 description 6
150000003833 nucleoside derivatives Chemical class 0.000 description 6
230000005855 radiation Effects 0.000 description 6
238000007423 screening assay Methods 0.000 description 6
238000003860 storage Methods 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
230000002103 transcriptional effect Effects 0.000 description 6
210000004881 tumor cell Anatomy 0.000 description 6
230000003612 virological effect Effects 0.000 description 6
102000004127 Cytokines Human genes 0.000 description 5
108090000695 Cytokines Proteins 0.000 description 5
102100020800 DNA damage-regulated autophagy modulator protein 1 Human genes 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
206010016654 Fibrosis Diseases 0.000 description 5
241000282412 Homo Species 0.000 description 5
101000931929 Homo sapiens DNA damage-regulated autophagy modulator protein 1 Proteins 0.000 description 5
206010058467 Lung neoplasm malignant Diseases 0.000 description 5
241000288906 Primates Species 0.000 description 5
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
150000001412 amines Chemical group 0.000 description 5
210000004102 animal cell Anatomy 0.000 description 5
238000010171 animal model Methods 0.000 description 5
230000001093 anti-cancer Effects 0.000 description 5
229960002685 biotin Drugs 0.000 description 5
235000020958 biotin Nutrition 0.000 description 5
239000011616 biotin Substances 0.000 description 5
210000001072 colon Anatomy 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
239000000470 constituent Substances 0.000 description 5
230000001186 cumulative effect Effects 0.000 description 5
239000002254 cytotoxic agent Substances 0.000 description 5
231100000599 cytotoxic agent Toxicity 0.000 description 5
230000003828 downregulation Effects 0.000 description 5
239000003623 enhancer Substances 0.000 description 5
102000037865 fusion proteins Human genes 0.000 description 5
108020001507 fusion proteins Proteins 0.000 description 5
210000004408 hybridoma Anatomy 0.000 description 5
229910052739 hydrogen Inorganic materials 0.000 description 5
239000001257 hydrogen Substances 0.000 description 5
238000003384 imaging method Methods 0.000 description 5
230000003053 immunization Effects 0.000 description 5
238000002649 immunization Methods 0.000 description 5
238000011065 in-situ storage Methods 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
238000002372 labelling Methods 0.000 description 5
230000003902 lesion Effects 0.000 description 5
201000005202 lung cancer Diseases 0.000 description 5
208000020816 lung neoplasm Diseases 0.000 description 5
238000004519 manufacturing process Methods 0.000 description 5
230000007246 mechanism Effects 0.000 description 5
239000002609 medium Substances 0.000 description 5
206010061289 metastatic neoplasm Diseases 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
230000028327 secretion Effects 0.000 description 5
210000003491 skin Anatomy 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000013519 translation Methods 0.000 description 5
241000283690 Bos taurus Species 0.000 description 4
108091003079 Bovine Serum Albumin Proteins 0.000 description 4
208000026310 Breast neoplasm Diseases 0.000 description 4
108010001857 Cell Surface Receptors Proteins 0.000 description 4
206010009944 Colon cancer Diseases 0.000 description 4
102000010834 Extracellular Matrix Proteins Human genes 0.000 description 4
108010037362 Extracellular Matrix Proteins Proteins 0.000 description 4
108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 4
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
241000764238 Isis Species 0.000 description 4
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 4
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 4
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical group CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 4
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
239000004472 Lysine Substances 0.000 description 4
108700026244 Open Reading Frames Proteins 0.000 description 4
102000035195 Peptidases Human genes 0.000 description 4
108091005804 Peptidases Proteins 0.000 description 4
108010076504 Protein Sorting Signals Proteins 0.000 description 4
108700008625 Reporter Genes Proteins 0.000 description 4
206010039491 Sarcoma Diseases 0.000 description 4
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
235000004279 alanine Nutrition 0.000 description 4
230000033115 angiogenesis Effects 0.000 description 4
229940049706 benzodiazepine Drugs 0.000 description 4
150000001557 benzodiazepines Chemical class 0.000 description 4
229940098773 bovine serum albumin Drugs 0.000 description 4
239000000872 buffer Substances 0.000 description 4
235000014633 carbohydrates Nutrition 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
230000004663 cell proliferation Effects 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000004590 computer program Methods 0.000 description 4
235000018417 cysteine Nutrition 0.000 description 4
230000003247 decreasing effect Effects 0.000 description 4
230000029087 digestion Effects 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
238000004520 electroporation Methods 0.000 description 4
210000002744 extracellular matrix Anatomy 0.000 description 4
230000004761 fibrosis Effects 0.000 description 4
239000011521 glass Substances 0.000 description 4
150000004676 glycans Chemical class 0.000 description 4
210000003128 head Anatomy 0.000 description 4
229940088597 hormone Drugs 0.000 description 4
239000005556 hormone Substances 0.000 description 4
230000002209 hydrophobic effect Effects 0.000 description 4
FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 4
238000009169 immunotherapy Methods 0.000 description 4
201000010260 leiomyoma Diseases 0.000 description 4
210000004698 lymphocyte Anatomy 0.000 description 4
239000011159 matrix material Substances 0.000 description 4
238000005259 measurement Methods 0.000 description 4
239000012528 membrane Substances 0.000 description 4
230000001394 metastastic effect Effects 0.000 description 4
229930182817 methionine Chemical group 0.000 description 4
102000035118 modified proteins Human genes 0.000 description 4
108091005573 modified proteins Proteins 0.000 description 4
230000035772 mutation Effects 0.000 description 4
125000003835 nucleoside group Chemical group 0.000 description 4
210000004940 nucleus Anatomy 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
210000002381 plasma Anatomy 0.000 description 4
239000004033 plastic Substances 0.000 description 4
229920003023 plastic Polymers 0.000 description 4
229920001282 polysaccharide Polymers 0.000 description 4
239000005017 polysaccharide Substances 0.000 description 4
238000012545 processing Methods 0.000 description 4
235000013930 proline Nutrition 0.000 description 4
238000000159 protein binding assay Methods 0.000 description 4
230000002285 radioactive effect Effects 0.000 description 4
230000010076 replication Effects 0.000 description 4
230000004044 response Effects 0.000 description 4
230000001177 retroviral effect Effects 0.000 description 4
238000000926 separation method Methods 0.000 description 4
235000004400 serine Nutrition 0.000 description 4
239000000243 solution Substances 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
230000009261 transgenic effect Effects 0.000 description 4
235000002374 tyrosine Nutrition 0.000 description 4
125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
230000003827 upregulation Effects 0.000 description 4
MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
239000004475 Arginine Substances 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
102000000844 Cell Surface Receptors Human genes 0.000 description 3
241000699800 Cricetinae Species 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
102100029098 Hypoxanthine-guanine phosphoribosyltransferase Human genes 0.000 description 3
108700005091 Immunoglobulin Genes Proteins 0.000 description 3
229930010555 Inosine Natural products 0.000 description 3
UGQMRVRMYYASKQ-KQYNXXCUSA-N Inosine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC(O)=C2N=C1 UGQMRVRMYYASKQ-KQYNXXCUSA-N 0.000 description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 3
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 3
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 3
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 3
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 3
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 3
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 3
208000019693 Lung disease Diseases 0.000 description 3
241000699660 Mus musculus Species 0.000 description 3
101710163270 Nuclease Proteins 0.000 description 3
239000004677 Nylon Substances 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
108010001014 Plasminogen Activators Proteins 0.000 description 3
102000001938 Plasminogen Activators Human genes 0.000 description 3
206010035664 Pneumonia Diseases 0.000 description 3
206010035742 Pneumonitis Diseases 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
239000004365 Protease Substances 0.000 description 3
102000001253 Protein Kinase Human genes 0.000 description 3
108020004511 Recombinant DNA Proteins 0.000 description 3
102000014400 SH2 domains Human genes 0.000 description 3
108050003452 SH2 domains Proteins 0.000 description 3
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
208000000453 Skin Neoplasms Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
206010068771 Soft tissue neoplasm Diseases 0.000 description 3
230000005867 T cell response Effects 0.000 description 3
108700019146 Transgenes Proteins 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
108700025716 Tumor Suppressor Genes Proteins 0.000 description 3
102000044209 Tumor Suppressor Genes Human genes 0.000 description 3
241000700605 Viruses Species 0.000 description 3
238000000137 annealing Methods 0.000 description 3
239000005557 antagonist Substances 0.000 description 3
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
208000006673 asthma Diseases 0.000 description 3
239000011230 binding agent Substances 0.000 description 3
210000000988 bone and bone Anatomy 0.000 description 3
210000000481 breast Anatomy 0.000 description 3
239000011575 calcium Substances 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
230000003833 cell viability Effects 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000003776 cleavage reaction Methods 0.000 description 3
230000005757 colony formation Effects 0.000 description 3
230000030944 contact inhibition Effects 0.000 description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
238000013500 data storage Methods 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
238000006073 displacement reaction Methods 0.000 description 3
210000003238 esophagus Anatomy 0.000 description 3
210000004602 germ cell Anatomy 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
235000014304 histidine Nutrition 0.000 description 3
238000002744 homologous recombination Methods 0.000 description 3
230000006801 homologous recombination Effects 0.000 description 3
229940072221 immunoglobulins Drugs 0.000 description 3
238000010348 incorporation Methods 0.000 description 3
230000006698 induction Effects 0.000 description 3
229960003786 inosine Drugs 0.000 description 3
150000002611 lead compounds Chemical class 0.000 description 3
210000000265 leukocyte Anatomy 0.000 description 3
238000007834 ligase chain reaction Methods 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
230000004807 localization Effects 0.000 description 3
230000036210 malignancy Effects 0.000 description 3
210000004379 membrane Anatomy 0.000 description 3
239000000178 monomer Substances 0.000 description 3
238000002703 mutagenesis Methods 0.000 description 3
231100000350 mutagenesis Toxicity 0.000 description 3
208000029974 neurofibrosarcoma Diseases 0.000 description 3
230000007935 neutral effect Effects 0.000 description 3
229920001778 nylon Polymers 0.000 description 3
230000008520 organization Effects 0.000 description 3
230000002611 ovarian Effects 0.000 description 3
239000002245 particle Substances 0.000 description 3
238000002823 phage display Methods 0.000 description 3
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 3
229940127126 plasminogen activator Drugs 0.000 description 3
229920001223 polyethylene glycol Polymers 0.000 description 3
239000002243 precursor Substances 0.000 description 3
230000008569 process Effects 0.000 description 3
238000011321 prophylaxis Methods 0.000 description 3
235000019419 proteases Nutrition 0.000 description 3
230000004952 protein activity Effects 0.000 description 3
108060006633 protein kinase Proteins 0.000 description 3
238000010791 quenching Methods 0.000 description 3
230000000171 quenching effect Effects 0.000 description 3
230000007017 scission Effects 0.000 description 3
230000003248 secreting effect Effects 0.000 description 3
230000035945 sensitivity Effects 0.000 description 3
201000000849 skin cancer Diseases 0.000 description 3
206010041823 squamous cell carcinoma Diseases 0.000 description 3
238000010561 standard procedure Methods 0.000 description 3
239000013589 supplement Substances 0.000 description 3
RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 description 3
125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 3
238000001890 transfection Methods 0.000 description 3
238000011830 transgenic mouse model Methods 0.000 description 3
230000029663 wound healing Effects 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
VPFUWHKTPYPNGT-UHFFFAOYSA-N 3-(3,4-dihydroxyphenyl)-1-(5-hydroxy-2,2-dimethylchromen-6-yl)propan-1-one Chemical compound OC1=C2C=CC(C)(C)OC2=CC=C1C(=O)CCC1=CC=C(O)C(O)=C1 VPFUWHKTPYPNGT-UHFFFAOYSA-N 0.000 description 2
LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
208000003200 Adenoma Diseases 0.000 description 2
102000009027 Albumins Human genes 0.000 description 2
108010088751 Albumins Proteins 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
108700028369 Alleles Proteins 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 2
201000003076 Angiosarcoma Diseases 0.000 description 2
244000063299 Bacillus subtilis Species 0.000 description 2
235000014469 Bacillus subtilis Nutrition 0.000 description 2
208000020084 Bone disease Diseases 0.000 description 2
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 2
241000282472 Canis lupus familiaris Species 0.000 description 2
102000014914 Carrier Proteins Human genes 0.000 description 2
108010078791 Carrier Proteins Proteins 0.000 description 2
208000005243 Chondrosarcoma Diseases 0.000 description 2
241000557626 Corvus corax Species 0.000 description 2
208000011231 Crohn disease Diseases 0.000 description 2
239000004971 Cross linker Substances 0.000 description 2
BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 2
102000001301 EGF receptor Human genes 0.000 description 2
108060006698 EGF receptor Proteins 0.000 description 2
101150029707 ERBB2 gene Proteins 0.000 description 2
206010014561 Emphysema Diseases 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
208000000461 Esophageal Neoplasms Diseases 0.000 description 2
208000006168 Ewing Sarcoma Diseases 0.000 description 2
241000282326 Felis catus Species 0.000 description 2
102000003688 G-Protein-Coupled Receptors Human genes 0.000 description 2
108090000045 G-Protein-Coupled Receptors Proteins 0.000 description 2
206010017708 Ganglioneuroblastoma Diseases 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
239000004471 Glycine Substances 0.000 description 2
AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
102000005744 Glycoside Hydrolases Human genes 0.000 description 2
108010031186 Glycoside Hydrolases Proteins 0.000 description 2
208000001258 Hemangiosarcoma Diseases 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 2
201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
206010061218 Inflammation Diseases 0.000 description 2
102100020873 Interleukin-2 Human genes 0.000 description 2
108010002350 Interleukin-2 Proteins 0.000 description 2
208000001126 Keratosis Diseases 0.000 description 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical group CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 2
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
108060001084 Luciferase Proteins 0.000 description 2
239000005089 Luciferase Substances 0.000 description 2
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
108010052285 Membrane Proteins Proteins 0.000 description 2
206010027406 Mesothelioma Diseases 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
101100366940 Mus musculus Stom gene Proteins 0.000 description 2
208000034176 Neoplasms, Germ Cell and Embryonal Diseases 0.000 description 2
201000004404 Neurofibroma Diseases 0.000 description 2
208000005890 Neuroma Diseases 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
206010030155 Oesophageal carcinoma Diseases 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
241001494479 Pecora Species 0.000 description 2
108010067902 Peptide Library Proteins 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
241000276498 Pollachius virens Species 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
208000037062 Polyps Diseases 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
206010063664 Presumed ocular histoplasmosis syndrome Diseases 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
206010038389 Renal cancer Diseases 0.000 description 2
208000006265 Renal cell carcinoma Diseases 0.000 description 2
238000012300 Sequence Analysis Methods 0.000 description 2
241000700584 Simplexvirus Species 0.000 description 2
108020004459 Small interfering RNA Proteins 0.000 description 2
FKNQFGJONOIPTF-UHFFFAOYSA-N Sodium cation Chemical compound [Na+] FKNQFGJONOIPTF-UHFFFAOYSA-N 0.000 description 2
208000021712 Soft tissue sarcoma Diseases 0.000 description 2
PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
206010043276 Teratoma Diseases 0.000 description 2
ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 2
241000700618 Vaccinia virus Species 0.000 description 2
206010046865 Vaccinia virus infection Diseases 0.000 description 2
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
108700005077 Viral Genes Proteins 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
230000001594 aberrant effect Effects 0.000 description 2
RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
238000001042 affinity chromatography Methods 0.000 description 2
230000005875 antibody response Effects 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
206010003246 arthritis Diseases 0.000 description 2
235000003704 aspartic acid Nutrition 0.000 description 2
210000003719 b-lymphocyte Anatomy 0.000 description 2
230000008901 benefit Effects 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
230000001588 bifunctional effect Effects 0.000 description 2
239000012867 bioactive agent Substances 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
230000008827 biological function Effects 0.000 description 2
230000008512 biological response Effects 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
230000037396 body weight Effects 0.000 description 2
210000004556 brain Anatomy 0.000 description 2
201000009267 bronchiectasis Diseases 0.000 description 2
239000001110 calcium chloride Substances 0.000 description 2
229910001628 calcium chloride Inorganic materials 0.000 description 2
235000011148 calcium chloride Nutrition 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
208000035269 cancer or benign tumor Diseases 0.000 description 2
230000000711 cancerogenic effect Effects 0.000 description 2
231100000357 carcinogen Toxicity 0.000 description 2
239000003183 carcinogenic agent Substances 0.000 description 2
208000002458 carcinoid tumor Diseases 0.000 description 2
230000015556 catabolic process Effects 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
230000032823 cell division Effects 0.000 description 2
210000003679 cervix uteri Anatomy 0.000 description 2
238000012512 characterization method Methods 0.000 description 2
230000002925 chemical effect Effects 0.000 description 2
238000004587 chromatography analysis Methods 0.000 description 2
230000014107 chromosome localization Effects 0.000 description 2
208000019425 cirrhosis of liver Diseases 0.000 description 2
230000001268 conjugating effect Effects 0.000 description 2
108091036078 conserved sequence Proteins 0.000 description 2
238000007596 consolidation process Methods 0.000 description 2
230000002596 correlated effect Effects 0.000 description 2
230000008878 coupling Effects 0.000 description 2
238000010168 coupling process Methods 0.000 description 2
238000005859 coupling reaction Methods 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
230000009260 cross reactivity Effects 0.000 description 2
OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
230000003013 cytotoxicity Effects 0.000 description 2
231100000135 cytotoxicity Toxicity 0.000 description 2
230000002950 deficient Effects 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000002405 diagnostic procedure Methods 0.000 description 2
239000000539 dimer Substances 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 description 2
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
210000001671 embryonic stem cell Anatomy 0.000 description 2
230000002124 endocrine Effects 0.000 description 2
208000001991 endodermal sinus tumor Diseases 0.000 description 2
230000007613 environmental effect Effects 0.000 description 2
201000004101 esophageal cancer Diseases 0.000 description 2
150000002148 esters Chemical class 0.000 description 2
210000003527 eukaryotic cell Anatomy 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000012530 fluid Substances 0.000 description 2
239000006260 foam Substances 0.000 description 2
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 2
201000008361 ganglioneuroma Diseases 0.000 description 2
108091008053 gene clusters Proteins 0.000 description 2
208000005017 glioblastoma Diseases 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
229930004094 glycosylphosphatidylinositol Natural products 0.000 description 2
208000003064 gonadoblastoma Diseases 0.000 description 2
201000006604 granular cell tumor Diseases 0.000 description 2
239000005090 green fluorescent protein Substances 0.000 description 2
UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
238000003306 harvesting Methods 0.000 description 2
208000014829 head and neck neoplasm Diseases 0.000 description 2
230000036541 health Effects 0.000 description 2
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
210000005260 human cell Anatomy 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
206010020718 hyperplasia Diseases 0.000 description 2
230000001900 immune effect Effects 0.000 description 2
238000003119 immunoblot Methods 0.000 description 2
230000001024 immunotherapeutic effect Effects 0.000 description 2
238000007901 in situ hybridization Methods 0.000 description 2
230000004054 inflammatory process Effects 0.000 description 2
208000036971 interstitial lung disease 2 Diseases 0.000 description 2
229910052742 iron Inorganic materials 0.000 description 2
DRAVOWXCEBXPTN-UHFFFAOYSA-N isoguanine Chemical compound NC1=NC(=O)NC2=C1NC=N2 DRAVOWXCEBXPTN-UHFFFAOYSA-N 0.000 description 2
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
229960000310 isoleucine Drugs 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
201000003265 lymphadenitis Diseases 0.000 description 2
208000012804 lymphangiosarcoma Diseases 0.000 description 2
230000005381 magnetic domain Effects 0.000 description 2
210000001161 mammalian embryo Anatomy 0.000 description 2
238000007726 management method Methods 0.000 description 2
238000004949 mass spectrometry Methods 0.000 description 2
238000001819 mass spectrum Methods 0.000 description 2
210000002752 melanocyte Anatomy 0.000 description 2
201000001441 melanoma Diseases 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
201000008806 mesenchymal cell neoplasm Diseases 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
208000037819 metastatic cancer Diseases 0.000 description 2
208000011575 metastatic malignant neoplasm Diseases 0.000 description 2
TWXDDNPPQUTEOV-FVGYRXGTSA-N methamphetamine hydrochloride Chemical compound Cl.CN[C@@H](C)CC1=CC=CC=C1 TWXDDNPPQUTEOV-FVGYRXGTSA-N 0.000 description 2
238000000520 microinjection Methods 0.000 description 2
239000004005 microsphere Substances 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
238000010369 molecular cloning Methods 0.000 description 2
229940035032 monophosphoryl lipid a Drugs 0.000 description 2
201000000050 myeloid neoplasm Diseases 0.000 description 2
210000003739 neck Anatomy 0.000 description 2
239000013642 negative control Substances 0.000 description 2
208000007538 neurilemmoma Diseases 0.000 description 2
208000029986 neuroepithelioma Diseases 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
230000009871 nonspecific binding Effects 0.000 description 2
238000011275 oncology therapy Methods 0.000 description 2
201000008968 osteosarcoma Diseases 0.000 description 2
208000007312 paraganglioma Diseases 0.000 description 2
230000036961 partial effect Effects 0.000 description 2
239000013610 patient sample Substances 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
150000004713 phosphodiesters Chemical group 0.000 description 2
150000003904 phospholipids Chemical class 0.000 description 2
PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
230000000704 physical effect Effects 0.000 description 2
230000004962 physiological condition Effects 0.000 description 2
230000035790 physiological processes and functions Effects 0.000 description 2
239000013612 plasmid Substances 0.000 description 2
230000008488 polyadenylation Effects 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000011591 potassium Substances 0.000 description 2
229910052700 potassium Inorganic materials 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
229940076155 protein modulator Drugs 0.000 description 2
238000001742 protein purification Methods 0.000 description 2
230000004850 protein–protein interaction Effects 0.000 description 2
208000005069 pulmonary fibrosis Diseases 0.000 description 2
150000003212 purines Chemical class 0.000 description 2
102000027426 receptor tyrosine kinases Human genes 0.000 description 2
108091008598 receptor tyrosine kinases Proteins 0.000 description 2
238000010188 recombinant method Methods 0.000 description 2
210000000664 rectum Anatomy 0.000 description 2
230000009467 reduction Effects 0.000 description 2
238000012552 review Methods 0.000 description 2
150000003290 ribose derivatives Chemical group 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
206010039667 schwannoma Diseases 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
239000000377 silicon dioxide Substances 0.000 description 2
239000011734 sodium Substances 0.000 description 2
229910052708 sodium Inorganic materials 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
229910001415 sodium ion Inorganic materials 0.000 description 2
210000004872 soft tissue Anatomy 0.000 description 2
238000007619 statistical method Methods 0.000 description 2
238000004114 suspension culture Methods 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
235000008521 threonine Nutrition 0.000 description 2
RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
231100000200 toxicological information Toxicity 0.000 description 2
238000012546 transfer Methods 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
241000701161 unidentified adenovirus Species 0.000 description 2
210000004291 uterus Anatomy 0.000 description 2
208000007089 vaccinia Diseases 0.000 description 2
239000004474 valine Substances 0.000 description 2
238000011179 visual inspection Methods 0.000 description 2
238000001262 western blot Methods 0.000 description 2
239000011701 zinc Substances 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
FXYPGCIGRDZWNR-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 3-[[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropyl]disulfanyl]propanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCSSCCC(=O)ON1C(=O)CCC1=O FXYPGCIGRDZWNR-UHFFFAOYSA-N 0.000 description 1
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
VHTNTJQSKJZERS-XUVCUMPTSA-N (2s,3s,4r,5s,6s)-2-methyl-6-methylselanyloxane-3,4,5-triol Chemical compound C[Se][C@@H]1O[C@@H](C)[C@@H](O)[C@@H](O)[C@@H]1O VHTNTJQSKJZERS-XUVCUMPTSA-N 0.000 description 1
UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
125000003287 1H-imidazol-4-ylmethyl group Chemical group [H]N1C([H])=NC(C([H])([H])[*])=C1[H] 0.000 description 1
150000003923 2,5-pyrrolediones Chemical class 0.000 description 1
XQCZBXHVTFVIFE-UHFFFAOYSA-N 2-amino-4-hydroxypyrimidine Chemical compound NC1=NC=CC(O)=N1 XQCZBXHVTFVIFE-UHFFFAOYSA-N 0.000 description 1
JRYMOPZHXMVHTA-DAGMQNCNSA-N 2-amino-7-[(2r,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1h-pyrrolo[2,3-d]pyrimidin-4-one Chemical compound C1=CC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O JRYMOPZHXMVHTA-DAGMQNCNSA-N 0.000 description 1
OZDAOHVKBFBBMZ-UHFFFAOYSA-N 2-aminopentanedioic acid;hydrate Chemical compound O.OC(=O)C(N)CCC(O)=O OZDAOHVKBFBBMZ-UHFFFAOYSA-N 0.000 description 1
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
BIGBDMFRWJRLGJ-UHFFFAOYSA-N 3-benzyl-1,5-didiazoniopenta-1,4-diene-2,4-diolate Chemical compound [N-]=[N+]=CC(=O)C(C(=O)C=[N+]=[N-])CC1=CC=CC=C1 BIGBDMFRWJRLGJ-UHFFFAOYSA-N 0.000 description 1
CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
NLPWSMKACWGINL-UHFFFAOYSA-N 4-azido-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(N=[N+]=[N-])C=C1O NLPWSMKACWGINL-UHFFFAOYSA-N 0.000 description 1
QRXMUCSWCMTJGU-UHFFFAOYSA-N 5-bromo-4-chloro-3-indolyl phosphate Chemical compound C1=C(Br)C(Cl)=C2C(OP(O)(=O)O)=CNC2=C1 QRXMUCSWCMTJGU-UHFFFAOYSA-N 0.000 description 1
108010066676 Abrin Proteins 0.000 description 1
206010000349 Acanthosis Diseases 0.000 description 1
241000251468 Actinopterygii Species 0.000 description 1
206010000830 Acute leukaemia Diseases 0.000 description 1
208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
229930024421 Adenine Natural products 0.000 description 1
GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
208000036764 Adenocarcinoma of the esophagus Diseases 0.000 description 1
206010051810 Angiomyolipoma Diseases 0.000 description 1
108020005544 Antisense RNA Proteins 0.000 description 1
241000203069 Archaea Species 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
206010003571 Astrocytoma Diseases 0.000 description 1
201000001320 Atherosclerosis Diseases 0.000 description 1
102100022717 Atypical chemokine receptor 1 Human genes 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
208000031729 Bacteremia Diseases 0.000 description 1
108020004513 Bacterial RNA Proteins 0.000 description 1
206010004146 Basal cell carcinoma Diseases 0.000 description 1
206010004446 Benign prostatic hyperplasia Diseases 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
102100026189 Beta-galactosidase Human genes 0.000 description 1
206010005949 Bone cancer Diseases 0.000 description 1
208000018084 Bone neoplasm Diseases 0.000 description 1
208000003174 Brain Neoplasms Diseases 0.000 description 1
208000014644 Brain disease Diseases 0.000 description 1
206010055113 Breast cancer metastatic Diseases 0.000 description 1
206010006458 Bronchitis chronic Diseases 0.000 description 1
125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
239000002126 C01EB10 - Adenosine Substances 0.000 description 1
229940124292 CD20 monoclonal antibody Drugs 0.000 description 1
241000222122 Candida albicans Species 0.000 description 1
241000222128 Candida maltosa Species 0.000 description 1
241000283707 Capra Species 0.000 description 1
208000009458 Carcinoma in Situ Diseases 0.000 description 1
108010076119 Caseins Proteins 0.000 description 1
102000011632 Caseins Human genes 0.000 description 1
241000700198 Cavia Species 0.000 description 1
241000700199 Cavia porcellus Species 0.000 description 1
206010008342 Cervix carcinoma Diseases 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
206010008805 Chromosomal abnormalities Diseases 0.000 description 1
208000031404 Chromosome Aberrations Diseases 0.000 description 1
208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
208000032544 Cicatrix Diseases 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
102100038385 Coiled-coil domain-containing protein R3HCC1L Human genes 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
102000029816 Collagenase Human genes 0.000 description 1
108060005980 Collagenase Proteins 0.000 description 1
208000001333 Colorectal Neoplasms Diseases 0.000 description 1
206010010356 Congenital anomaly Diseases 0.000 description 1
108091035707 Consensus sequence Proteins 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
208000009798 Craniopharyngioma Diseases 0.000 description 1
108700032819 Croton tiglium crotin II Proteins 0.000 description 1
101710095468 Cyclase Proteins 0.000 description 1
102100033245 Cyclin-dependent kinase 16 Human genes 0.000 description 1
201000005171 Cystadenoma Diseases 0.000 description 1
IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
108010092160 Dactinomycin Proteins 0.000 description 1
CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 1
241000702421 Dependoparvovirus Species 0.000 description 1
208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
206010012689 Diabetic retinopathy Diseases 0.000 description 1
SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
206010013710 Drug interaction Diseases 0.000 description 1
208000007033 Dysgerminoma Diseases 0.000 description 1
206010058314 Dysplasia Diseases 0.000 description 1
101710202200 Endolysin A Proteins 0.000 description 1
201000009273 Endometriosis Diseases 0.000 description 1
108010042407 Endonucleases Proteins 0.000 description 1
102000004533 Endonucleases Human genes 0.000 description 1
101710199605 Endoribonuclease Proteins 0.000 description 1
206010014967 Ependymoma Diseases 0.000 description 1
241000283086 Equidae Species 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
108091029865 Exogenous DNA Proteins 0.000 description 1
101710082714 Exotoxin A Proteins 0.000 description 1
206010053487 Exposure to toxic agent Diseases 0.000 description 1
201000006107 Familial adenomatous polyposis Diseases 0.000 description 1
241000192125 Firmicutes Species 0.000 description 1
BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 1
208000000666 Fowlpox Diseases 0.000 description 1
241000233866 Fungi Species 0.000 description 1
206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
208000032612 Glial tumor Diseases 0.000 description 1
206010018338 Glioma Diseases 0.000 description 1
201000005618 Glomus Tumor Diseases 0.000 description 1
102000042092 Glucose transporter family Human genes 0.000 description 1
108091052347 Glucose transporter family Proteins 0.000 description 1
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 1
208000005234 Granulosa Cell Tumor Diseases 0.000 description 1
108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
102000004144 Green Fluorescent Proteins Human genes 0.000 description 1
241000941423 Grom virus Species 0.000 description 1
HVLSXIKZNLPZJJ-TXZCQADKSA-N HA peptide Chemical compound C([C@@H](C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 HVLSXIKZNLPZJJ-TXZCQADKSA-N 0.000 description 1
101150105462 HIS6 gene Proteins 0.000 description 1
208000006050 Hemangiopericytoma Diseases 0.000 description 1
229920000209 Hexadimethrine bromide Polymers 0.000 description 1
LYCVKHSJGDMDLM-LURJTMIESA-N His-Gly Chemical compound OC(=O)CNC(=O)[C@@H](N)CC1=CN=CN1 LYCVKHSJGDMDLM-LURJTMIESA-N 0.000 description 1
108010088652 Histocompatibility Antigens Class I Proteins 0.000 description 1
102000008949 Histocompatibility Antigens Class I Human genes 0.000 description 1
208000017604 Hodgkin disease Diseases 0.000 description 1
208000021519 Hodgkin lymphoma Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
101000678879 Homo sapiens Atypical chemokine receptor 1 Proteins 0.000 description 1
101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
101000743767 Homo sapiens Coiled-coil domain-containing protein R3HCC1L Proteins 0.000 description 1
101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
102000003839 Human Proteins Human genes 0.000 description 1
108090000144 Human Proteins Proteins 0.000 description 1
108090000320 Hyaluronan Synthases Proteins 0.000 description 1
102000003918 Hyaluronan Synthases Human genes 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
206010020649 Hyperkeratosis Diseases 0.000 description 1
206010021143 Hypoxia Diseases 0.000 description 1
102000009786 Immunoglobulin Constant Regions Human genes 0.000 description 1
108010009817 Immunoglobulin Constant Regions Proteins 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
102000012745 Immunoglobulin Subunits Human genes 0.000 description 1
108010079585 Immunoglobulin Subunits Proteins 0.000 description 1
108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
208000022559 Inflammatory bowel disease Diseases 0.000 description 1
102000003746 Insulin Receptor Human genes 0.000 description 1
108010001127 Insulin Receptor Proteins 0.000 description 1
102000019223 Interleukin-1 receptor Human genes 0.000 description 1
108050006617 Interleukin-1 receptor Proteins 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010038453 Interleukin-2 Receptors Proteins 0.000 description 1
102000010789 Interleukin-2 Receptors Human genes 0.000 description 1
102100021592 Interleukin-7 Human genes 0.000 description 1
108010002586 Interleukin-7 Proteins 0.000 description 1
208000029523 Interstitial Lung disease Diseases 0.000 description 1
208000037396 Intraductal Noninfiltrating Carcinoma Diseases 0.000 description 1
206010073094 Intraductal proliferative breast lesion Diseases 0.000 description 1
208000003456 Juvenile Arthritis Diseases 0.000 description 1
208000007766 Kaposi sarcoma Diseases 0.000 description 1
208000002260 Keloid Diseases 0.000 description 1
206010023330 Keloid scar Diseases 0.000 description 1
208000008839 Kidney Neoplasms Diseases 0.000 description 1
244000285963 Kluyveromyces fragilis Species 0.000 description 1
235000014663 Kluyveromyces fragilis Nutrition 0.000 description 1
241001138401 Kluyveromyces lactis Species 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical group OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
QEFRNWWLZKMPFJ-ZXPFJRLXSA-N L-methionine (R)-S-oxide Chemical group C[S@@](=O)CC[C@H]([NH3+])C([O-])=O QEFRNWWLZKMPFJ-ZXPFJRLXSA-N 0.000 description 1
QEFRNWWLZKMPFJ-UHFFFAOYSA-N L-methionine sulphoxide Chemical group CS(=O)CCC(N)C(O)=O QEFRNWWLZKMPFJ-UHFFFAOYSA-N 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
108010001831 LDL receptors Proteins 0.000 description 1
241000194034 Lactococcus lactis subsp. cremoris Species 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
208000018142 Leiomyosarcoma Diseases 0.000 description 1
241000270322 Lepidosauria Species 0.000 description 1
102100031775 Leptin receptor Human genes 0.000 description 1
201000004462 Leydig Cell Tumor Diseases 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
206010024612 Lipoma Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010073099 Lobular breast carcinoma in situ Diseases 0.000 description 1
102100024640 Low-density lipoprotein receptor Human genes 0.000 description 1
DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 1
206010025219 Lymphangioma Diseases 0.000 description 1
208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
206010061269 Malignant peritoneal neoplasm Diseases 0.000 description 1
208000025205 Mantle-Cell Lymphoma Diseases 0.000 description 1
102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
108010016160 Matrix Metalloproteinase 3 Proteins 0.000 description 1
102000018697 Membrane Proteins Human genes 0.000 description 1
208000024556 Mendelian disease Diseases 0.000 description 1
208000002030 Merkel cell carcinoma Diseases 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241000713333 Mouse mammary tumor virus Species 0.000 description 1
208000003445 Mouth Neoplasms Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical class ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 1
108091061960 Naked DNA Proteins 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
208000034179 Neoplasms, Glandular and Epithelial Diseases 0.000 description 1
206010029113 Neovascularisation Diseases 0.000 description 1
108010025020 Nerve Growth Factor Proteins 0.000 description 1
102000007072 Nerve Growth Factors Human genes 0.000 description 1
206010029260 Neuroblastoma Diseases 0.000 description 1
206010029266 Neuroendocrine carcinoma of the skin Diseases 0.000 description 1
241000221960 Neurospora Species 0.000 description 1
101100395023 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) his-7 gene Proteins 0.000 description 1
208000007256 Nevus Diseases 0.000 description 1
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
238000000636 Northern blotting Methods 0.000 description 1
108010077850 Nuclear Localization Signals Proteins 0.000 description 1
108091007494 Nucleic acid- binding domains Proteins 0.000 description 1
230000004989 O-glycosylation Effects 0.000 description 1
206010030137 Oesophageal adenocarcinoma Diseases 0.000 description 1
206010030216 Oesophagitis Diseases 0.000 description 1
241000320412 Ogataea angusta Species 0.000 description 1
201000010133 Oligodendroglioma Diseases 0.000 description 1
108020005187 Oligonucleotide Probes Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
206010048757 Oncocytoma Diseases 0.000 description 1
241000283283 Orcinus orca Species 0.000 description 1
206010033128 Ovarian cancer Diseases 0.000 description 1
206010061535 Ovarian neoplasm Diseases 0.000 description 1
208000012868 Overgrowth Diseases 0.000 description 1
208000002063 Oxyphilic Adenoma Diseases 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
241000282577 Pan troglodytes Species 0.000 description 1
206010061902 Pancreatic neoplasm Diseases 0.000 description 1
206010061332 Paraganglion neoplasm Diseases 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108010043958 Peptoids Proteins 0.000 description 1
208000027190 Peripheral T-cell lymphomas Diseases 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
241000235648 Pichia Species 0.000 description 1
206010050487 Pinealoblastoma Diseases 0.000 description 1
208000007641 Pinealoma Diseases 0.000 description 1
102100038124 Plasminogen Human genes 0.000 description 1
239000004743 Polypropylene Substances 0.000 description 1
208000032236 Predisposition to disease Diseases 0.000 description 1
102100033237 Pro-epidermal growth factor Human genes 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
238000012341 Quantitative reverse-transcriptase PCR Methods 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
108020004518 RNA Probes Proteins 0.000 description 1
238000012228 RNA interference-mediated gene silencing Methods 0.000 description 1
239000003391 RNA probe Substances 0.000 description 1
208000015634 Rectal Neoplasms Diseases 0.000 description 1
208000008938 Rhabdoid tumor Diseases 0.000 description 1
208000005678 Rhabdomyoma Diseases 0.000 description 1
108090000621 Ribonuclease P Proteins 0.000 description 1
102000004167 Ribonuclease P Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
108091028664 Ribonucleotide Proteins 0.000 description 1
108010039491 Ricin Proteins 0.000 description 1
238000011579 SCID mouse model Methods 0.000 description 1
102000000395 SH3 domains Human genes 0.000 description 1
108050008861 SH3 domains Proteins 0.000 description 1
241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
108010084592 Saporins Proteins 0.000 description 1
241000235347 Schizosaccharomyces pombe Species 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
201000010208 Seminoma Diseases 0.000 description 1
101710113029 Serine/threonine-protein kinase Proteins 0.000 description 1
208000003274 Sertoli cell tumor Diseases 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
208000003252 Signet Ring Cell Carcinoma Diseases 0.000 description 1
XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
208000016247 Soft tissue disease Diseases 0.000 description 1
102000004584 Somatomedin Receptors Human genes 0.000 description 1
108010017622 Somatomedin Receptors Proteins 0.000 description 1
241000251131 Sphyrna Species 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000005718 Stomach Neoplasms Diseases 0.000 description 1
241000194017 Streptococcus Species 0.000 description 1
235000014962 Streptococcus cremoris Nutrition 0.000 description 1
238000000692 Student's t-test Methods 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
101000930762 Sulfolobus acidocaldarius (strain ATCC 33909 / DSM 639 / JCM 8929 / NBRC 15157 / NCIMB 11770) Signal recognition particle receptor FtsY Proteins 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
108091008874 T cell receptors Proteins 0.000 description 1
102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
208000031672 T-Cell Peripheral Lymphoma Diseases 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
208000024313 Testicular Neoplasms Diseases 0.000 description 1
208000011622 Testicular disease Diseases 0.000 description 1
201000000331 Testicular germ cell cancer Diseases 0.000 description 1
206010057644 Testis cancer Diseases 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
208000010183 Thymus Hyperplasia Diseases 0.000 description 1
102100033504 Thyroglobulin Human genes 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
102000040945 Transcription factor Human genes 0.000 description 1
108091023040 Transcription factor Proteins 0.000 description 1
101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
108010033576 Transferrin Receptors Proteins 0.000 description 1
102100026144 Transferrin receptor protein 1 Human genes 0.000 description 1
HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
102000004243 Tubulin Human genes 0.000 description 1
108090000704 Tubulin Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
208000002495 Uterine Neoplasms Diseases 0.000 description 1
208000016599 Uterine disease Diseases 0.000 description 1
206010046798 Uterine leiomyoma Diseases 0.000 description 1
241000251539 Vertebrata <Metazoa> Species 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
208000004354 Vulvar Neoplasms Diseases 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
206010048215 Xanthomatosis Diseases 0.000 description 1
241000235015 Yarrowia lipolytica Species 0.000 description 1
208000012018 Yolk sac tumor Diseases 0.000 description 1
240000008042 Zea mays Species 0.000 description 1
235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
235000002017 Zea mays subsp mays Nutrition 0.000 description 1
102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
UZQJVUCHXGYFLQ-AYDHOLPZSA-N [(2s,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-4-[(2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hy Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O)O[C@H]1CC[C@]2(C)[C@H]3CC=C4[C@@]([C@@]3(CC[C@H]2[C@@]1(C=O)C)C)(C)CC(O)[C@]1(CCC(CC14)(C)C)C(=O)O[C@H]1[C@@H]([C@@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O[C@H]4[C@@H]([C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)[C@H](O)[C@@H](CO)O4)O)[C@H](O)[C@@H](CO)O3)O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UZQJVUCHXGYFLQ-AYDHOLPZSA-N 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000009825 accumulation Methods 0.000 description 1
230000021736 acetylation Effects 0.000 description 1
238000006640 acetylation reaction Methods 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
229920006397 acrylic thermoplastic Polymers 0.000 description 1
RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
230000036982 action potential Effects 0.000 description 1
230000003213 activating effect Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
229960000643 adenine Drugs 0.000 description 1
201000000452 adenoid squamous cell carcinoma Diseases 0.000 description 1
201000001256 adenosarcoma Diseases 0.000 description 1
229960005305 adenosine Drugs 0.000 description 1
201000008395 adenosquamous carcinoma Diseases 0.000 description 1
102000030621 adenylate cyclase Human genes 0.000 description 1
108060000200 adenylate cyclase Proteins 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
239000000556 agonist Substances 0.000 description 1
PPQRONHOSHZGFQ-LMVFSUKVSA-N aldehydo-D-ribose 5-phosphate Chemical group OP(=O)(O)OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PPQRONHOSHZGFQ-LMVFSUKVSA-N 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
229940037003 alum Drugs 0.000 description 1
AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
229940024545 aluminum hydroxide Drugs 0.000 description 1
229940024546 aluminum hydroxide gel Drugs 0.000 description 1
SMYKVLBUSSNXMV-UHFFFAOYSA-K aluminum;trihydroxide;hydrate Chemical compound O.[OH-].[OH-].[OH-].[Al+3] SMYKVLBUSSNXMV-UHFFFAOYSA-K 0.000 description 1
230000009435 amidation Effects 0.000 description 1
238000007112 amidation reaction Methods 0.000 description 1
229960003896 aminopterin Drugs 0.000 description 1
238000012870 ammonium sulfate precipitation Methods 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
239000002870 angiogenesis inducing agent Substances 0.000 description 1
230000008485 antagonism Effects 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000074 antisense oligonucleotide Substances 0.000 description 1
238000012230 antisense oligonucleotides Methods 0.000 description 1
239000008365 aqueous carrier Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
FIVPIPIDMRVLAY-UHFFFAOYSA-N aspergillin Natural products C1C2=CC=CC(O)C2N2C1(SS1)C(=O)N(C)C1(CO)C2=O FIVPIPIDMRVLAY-UHFFFAOYSA-N 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
239000005667 attractant Substances 0.000 description 1
108010044540 auristatin Proteins 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
230000008267 autocrine signaling Effects 0.000 description 1
230000035578 autophosphorylation Effects 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
210000000270 basal cell Anatomy 0.000 description 1
210000003651 basophil Anatomy 0.000 description 1
239000011324 bead Substances 0.000 description 1
235000013405 beer Nutrition 0.000 description 1
208000012999 benign epithelial neoplasm Diseases 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
108010005774 beta-Galactosidase Proteins 0.000 description 1
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
210000000941 bile Anatomy 0.000 description 1
210000000013 bile duct Anatomy 0.000 description 1
238000001574 biopsy Methods 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
238000006664 bond formation reaction Methods 0.000 description 1
210000004958 brain cell Anatomy 0.000 description 1
201000005389 breast carcinoma in situ Diseases 0.000 description 1
208000030270 breast disease Diseases 0.000 description 1
238000009395 breeding Methods 0.000 description 1
230000001488 breeding effect Effects 0.000 description 1
206010006451 bronchitis Diseases 0.000 description 1
239000007975 buffered saline Substances 0.000 description 1
239000006172 buffering agent Substances 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
231100000315 carcinogenic Toxicity 0.000 description 1
239000005018 casein Substances 0.000 description 1
BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
235000021240 caseins Nutrition 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
230000033366 cell cycle process Effects 0.000 description 1
230000024245 cell differentiation Effects 0.000 description 1
230000003915 cell function Effects 0.000 description 1
238000002701 cell growth assay Methods 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
238000001516 cell proliferation assay Methods 0.000 description 1
230000019522 cellular metabolic process Effects 0.000 description 1
230000004640 cellular pathway Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
230000036755 cellular response Effects 0.000 description 1
201000010881 cervical cancer Diseases 0.000 description 1
230000003196 chaotropic effect Effects 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
230000009920 chelation Effects 0.000 description 1
238000009614 chemical analysis method Methods 0.000 description 1
238000010382 chemical cross-linking Methods 0.000 description 1
150000005829 chemical entities Chemical class 0.000 description 1
125000003636 chemical group Chemical group 0.000 description 1
239000013626 chemical specie Substances 0.000 description 1
239000002975 chemoattractant Substances 0.000 description 1
230000031902 chemoattractant activity Effects 0.000 description 1
238000002512 chemotherapy Methods 0.000 description 1
229940044683 chemotherapy drug Drugs 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
208000020719 chondrogenic neoplasm Diseases 0.000 description 1
238000011098 chromatofocusing Methods 0.000 description 1
208000007451 chronic bronchitis Diseases 0.000 description 1
208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
229960004316 cisplatin Drugs 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
208000029664 classic familial adenomatous polyposis Diseases 0.000 description 1
229960002424 collagenase Drugs 0.000 description 1
208000029742 colonic neoplasm Diseases 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000004891 communication Methods 0.000 description 1
238000012875 competitive assay Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
239000003184 complementary RNA Substances 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
239000002131 composite material Substances 0.000 description 1
238000013329 compounding Methods 0.000 description 1
230000021615 conjugation Effects 0.000 description 1
239000000356 contaminant Substances 0.000 description 1
229920001577 copolymer Polymers 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
235000005822 corn Nutrition 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
238000012258 culturing Methods 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
208000017763 cutaneous neuroendocrine carcinoma Diseases 0.000 description 1
208000031513 cyst Diseases 0.000 description 1
208000002445 cystadenocarcinoma Diseases 0.000 description 1
150000001945 cysteines Chemical class 0.000 description 1
102000003675 cytokine receptors Human genes 0.000 description 1
108010057085 cytokine receptors Proteins 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
229940104302 cytosine Drugs 0.000 description 1
229960000640 dactinomycin Drugs 0.000 description 1
238000007405 data analysis Methods 0.000 description 1
238000007418 data mining Methods 0.000 description 1
230000006240 deamidation Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
231100000517 death Toxicity 0.000 description 1
230000022811 deglycosylation Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
108010005905 delta-hGHR Proteins 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000001212 derivatisation Methods 0.000 description 1
210000004207 dermis Anatomy 0.000 description 1
201000005620 dermis tumor Diseases 0.000 description 1
238000013461 design Methods 0.000 description 1
230000000368 destabilizing effect Effects 0.000 description 1
230000009025 developmental regulation Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
235000005911 diet Nutrition 0.000 description 1
230000037213 diet Effects 0.000 description 1
235000014113 dietary fatty acids Nutrition 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
238000003748 differential diagnosis Methods 0.000 description 1
QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 description 1
SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
206010013023 diphtheria Diseases 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
238000009510 drug design Methods 0.000 description 1
238000009509 drug development Methods 0.000 description 1
238000007876 drug discovery Methods 0.000 description 1
239000003596 drug target Substances 0.000 description 1
238000003255 drug test Methods 0.000 description 1
208000028715 ductal breast carcinoma in situ Diseases 0.000 description 1
201000007273 ductal carcinoma in situ Diseases 0.000 description 1
230000000235 effect on cancer Effects 0.000 description 1
230000002500 effect on skin Effects 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
210000002257 embryonic structure Anatomy 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000005538 encapsulation Methods 0.000 description 1
230000012202 endocytosis Effects 0.000 description 1
210000002889 endothelial cell Anatomy 0.000 description 1
108010028531 enomycin Proteins 0.000 description 1
230000029578 entry into host Effects 0.000 description 1
230000007071 enzymatic hydrolysis Effects 0.000 description 1
238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
239000002532 enzyme inhibitor Substances 0.000 description 1
229940125532 enzyme inhibitor Drugs 0.000 description 1
210000003979 eosinophil Anatomy 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
208000028653 esophageal adenocarcinoma Diseases 0.000 description 1
208000028299 esophageal disease Diseases 0.000 description 1
208000006881 esophagitis Diseases 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
210000001508 eye Anatomy 0.000 description 1
229930195729 fatty acid Natural products 0.000 description 1
239000000194 fatty acid Substances 0.000 description 1
150000004665 fatty acids Chemical class 0.000 description 1
206010016629 fibroma Diseases 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
201000003444 follicular lymphoma Diseases 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000013467 fragmentation Methods 0.000 description 1
238000006062 fragmentation reaction Methods 0.000 description 1
238000002825 functional assay Methods 0.000 description 1
230000002538 fungal effect Effects 0.000 description 1
210000000232 gallbladder Anatomy 0.000 description 1
UHBYWPGGCSDKFX-VKHMYHEASA-N gamma-carboxy-L-glutamic acid Chemical compound OC(=O)[C@@H](N)CC(C(O)=O)C(O)=O UHBYWPGGCSDKFX-VKHMYHEASA-N 0.000 description 1
206010017758 gastric cancer Diseases 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000003209 gene knockout Methods 0.000 description 1
238000010363 gene targeting Methods 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
150000002338 glycosides Chemical class 0.000 description 1
230000002710 gonadal effect Effects 0.000 description 1
210000004209 hair Anatomy 0.000 description 1
201000009277 hairy cell leukemia Diseases 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
210000002216 heart Anatomy 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
201000011066 hemangioma Diseases 0.000 description 1
101150030470 hepC gene Proteins 0.000 description 1
229940022353 herceptin Drugs 0.000 description 1
125000004404 heteroalkyl group Chemical group 0.000 description 1
125000000623 heterocyclic group Chemical group 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
238000012203 high throughput assay Methods 0.000 description 1
150000002411 histidines Chemical class 0.000 description 1
230000002962 histologic effect Effects 0.000 description 1
150000001469 hydantoins Chemical class 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
125000001165 hydrophobic group Chemical group 0.000 description 1
230000033444 hydroxylation Effects 0.000 description 1
238000005805 hydroxylation reaction Methods 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
230000001969 hypertrophic effect Effects 0.000 description 1
210000003026 hypopharynx Anatomy 0.000 description 1
230000007954 hypoxia Effects 0.000 description 1
150000002463 imidates Chemical class 0.000 description 1
230000003100 immobilizing effect Effects 0.000 description 1
230000036039 immunity Effects 0.000 description 1
230000009851 immunogenic response Effects 0.000 description 1
230000005847 immunogenicity Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000011293 immunotherapeutic strategy Methods 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
201000004933 in situ carcinoma Diseases 0.000 description 1
238000000099 in vitro assay Methods 0.000 description 1
238000005462 in vivo assay Methods 0.000 description 1
230000000415 inactivating effect Effects 0.000 description 1
230000002779 inactivation Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
208000027866 inflammatory disease Diseases 0.000 description 1
206010022000 influenza Diseases 0.000 description 1
230000000977 initiatory effect Effects 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000008611 intercellular interaction Effects 0.000 description 1
102000002467 interleukin receptors Human genes 0.000 description 1
108010093036 interleukin receptors Proteins 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
201000010985 invasive ductal carcinoma Diseases 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
230000000302 ischemic effect Effects 0.000 description 1
238000001155 isoelectric focusing Methods 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
230000000155 isotopic effect Effects 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
210000001117 keloid Anatomy 0.000 description 1
108010045069 keyhole-limpet hemocyanin Proteins 0.000 description 1
201000010982 kidney cancer Diseases 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
238000011005 laboratory method Methods 0.000 description 1
210000004561 lacrimal apparatus Anatomy 0.000 description 1
239000008101 lactose Substances 0.000 description 1
208000003849 large cell carcinoma Diseases 0.000 description 1
210000002429 large intestine Anatomy 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
230000002045 lasting effect Effects 0.000 description 1
239000010410 layer Substances 0.000 description 1
206010024217 lentigo Diseases 0.000 description 1
108010019813 leptin receptors Proteins 0.000 description 1
208000013104 leukocyte disease Diseases 0.000 description 1
238000000670 ligand binding assay Methods 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
210000000088 lip Anatomy 0.000 description 1
208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 1
150000002632 lipids Chemical class 0.000 description 1
239000007788 liquid Substances 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
244000144972 livestock Species 0.000 description 1
201000011059 lobular neoplasia Diseases 0.000 description 1
230000007774 longterm Effects 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
201000009546 lung large cell carcinoma Diseases 0.000 description 1
208000037841 lung tumor Diseases 0.000 description 1
210000002751 lymph Anatomy 0.000 description 1
210000001165 lymph node Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
230000002101 lytic effect Effects 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
208000020968 mature T-cell and NK-cell non-Hodgkin lymphoma Diseases 0.000 description 1
206010027191 meningioma Diseases 0.000 description 1
150000002739 metals Chemical class 0.000 description 1
238000003358 metastasis assay Methods 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
YCXSYMVGMXQYNT-UHFFFAOYSA-N methyl 3-[(4-azidophenyl)disulfanyl]propanimidate Chemical compound COC(=N)CCSSC1=CC=C(N=[N+]=[N-])C=C1 YCXSYMVGMXQYNT-UHFFFAOYSA-N 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
LSDPWZHWYPCBBB-UHFFFAOYSA-O methylsulfide anion Chemical compound [SH2+]C LSDPWZHWYPCBBB-UHFFFAOYSA-O 0.000 description 1
239000010445 mica Substances 0.000 description 1
229910052618 mica group Inorganic materials 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
238000000386 microscopy Methods 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
239000003226 mitogen Substances 0.000 description 1
201000010225 mixed cell type cancer Diseases 0.000 description 1
208000029638 mixed neoplasm Diseases 0.000 description 1
238000002156 mixing Methods 0.000 description 1
108091005601 modified peptides Proteins 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000000214 mouth Anatomy 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
238000002887 multiple sequence alignment Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
210000003928 nasal cavity Anatomy 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
230000001613 neoplastic effect Effects 0.000 description 1
210000000653 nervous system Anatomy 0.000 description 1
201000011682 nervous system cancer Diseases 0.000 description 1
239000003900 neurotrophic factor Substances 0.000 description 1
239000002547 new drug Substances 0.000 description 1
229910017604 nitric acid Inorganic materials 0.000 description 1
JPXMTWWFLBLUCD-UHFFFAOYSA-N nitro blue tetrazolium(2+) Chemical compound COC1=CC(C=2C=C(OC)C(=CC=2)[N+]=2N(N=C(N=2)C=2C=CC=CC=2)C=2C=CC(=CC=2)[N+]([O-])=O)=CC=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=C([N+]([O-])=O)C=C1 JPXMTWWFLBLUCD-UHFFFAOYSA-N 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
230000000683 nonmetastatic effect Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
238000007826 nucleic acid assay Methods 0.000 description 1
239000002751 oligonucleotide probe Substances 0.000 description 1
239000013307 optical fiber Substances 0.000 description 1
238000005457 optimization Methods 0.000 description 1
210000003463 organelle Anatomy 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
229940127084 other anti-cancer agent Drugs 0.000 description 1
208000015124 ovarian disease Diseases 0.000 description 1
201000010302 ovarian serous cystadenocarcinoma Diseases 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
210000003101 oviduct Anatomy 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
125000004043 oxo group Chemical group O=* 0.000 description 1
239000003002 pH adjusting agent Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
201000002528 pancreatic cancer Diseases 0.000 description 1
208000008443 pancreatic carcinoma Diseases 0.000 description 1
210000000277 pancreatic duct Anatomy 0.000 description 1
208000002820 pancreatoblastoma Diseases 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
201000010148 papillary adenoma Diseases 0.000 description 1
201000010198 papillary carcinoma Diseases 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
210000003695 paranasal sinus Anatomy 0.000 description 1
102000045222 parkin Human genes 0.000 description 1
230000007310 pathophysiology Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
230000035515 penetration Effects 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
239000000816 peptidomimetic Substances 0.000 description 1
210000005105 peripheral blood lymphocyte Anatomy 0.000 description 1
210000001428 peripheral nervous system Anatomy 0.000 description 1
210000001322 periplasm Anatomy 0.000 description 1
201000002524 peritoneal carcinoma Diseases 0.000 description 1
230000002974 pharmacogenomic effect Effects 0.000 description 1
239000002831 pharmacologic agent Substances 0.000 description 1
210000003800 pharynx Anatomy 0.000 description 1
HTYIXCKSEQQCJO-UHFFFAOYSA-N phenaglycodol Chemical compound CC(C)(O)C(C)(O)C1=CC=C(Cl)C=C1 HTYIXCKSEQQCJO-UHFFFAOYSA-N 0.000 description 1
108010076042 phenomycin Proteins 0.000 description 1
238000003566 phosphorylation assay Methods 0.000 description 1
BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
230000002186 photoactivation Effects 0.000 description 1
230000035479 physiological effects, processes and functions Effects 0.000 description 1
239000006187 pill Substances 0.000 description 1
201000003113 pineoblastoma Diseases 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
208000010626 plasma cell neoplasm Diseases 0.000 description 1
229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
229920002627 poly(phosphazenes) Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
229920001748 polybutylene Polymers 0.000 description 1
208000024246 polyembryoma Diseases 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
210000004896 polypeptide structure Anatomy 0.000 description 1
229920001155 polypropylene Polymers 0.000 description 1
229920001451 polypropylene glycol Polymers 0.000 description 1
239000004814 polyurethane Substances 0.000 description 1
229920002635 polyurethane Polymers 0.000 description 1
239000013641 positive control Substances 0.000 description 1
230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
239000001103 potassium chloride Substances 0.000 description 1
235000011164 potassium chloride Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
150000003141 primary amines Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
210000001236 prokaryotic cell Anatomy 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
210000002307 prostate Anatomy 0.000 description 1
208000017497 prostate disease Diseases 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
239000003223 protective agent Substances 0.000 description 1
108020001580 protein domains Proteins 0.000 description 1
230000004853 protein function Effects 0.000 description 1
229940023143 protein vaccine Drugs 0.000 description 1
210000001938 protoplast Anatomy 0.000 description 1
208000013368 pseudoglandular squamous cell carcinoma Diseases 0.000 description 1
239000012264 purified product Substances 0.000 description 1
150000003230 pyrimidines Chemical class 0.000 description 1
150000003235 pyrrolidines Chemical class 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
238000001959 radiotherapy Methods 0.000 description 1
238000002708 random mutagenesis Methods 0.000 description 1
238000003753 real-time PCR Methods 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
102000027427 receptor guanylyl cyclases Human genes 0.000 description 1
108091008596 receptor guanylyl cyclases Proteins 0.000 description 1
238000003259 recombinant expression Methods 0.000 description 1
206010038038 rectal cancer Diseases 0.000 description 1
201000001275 rectum cancer Diseases 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000007634 remodeling Methods 0.000 description 1
201000010174 renal carcinoma Diseases 0.000 description 1
201000002793 renal fibrosis Diseases 0.000 description 1
201000007444 renal pelvis carcinoma Diseases 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000003571 reporter gene assay Methods 0.000 description 1
230000001850 reproductive effect Effects 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
230000002207 retinal effect Effects 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
238000004007 reversed phase HPLC Methods 0.000 description 1
201000009410 rhabdomyosarcoma Diseases 0.000 description 1
PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 description 1
239000002336 ribonucleotide Substances 0.000 description 1
125000002652 ribonucleotide group Chemical group 0.000 description 1
210000003705 ribosome Anatomy 0.000 description 1
239000011435 rock Substances 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
210000003079 salivary gland Anatomy 0.000 description 1
238000005464 sample preparation method Methods 0.000 description 1
231100000241 scar Toxicity 0.000 description 1
230000037387 scars Effects 0.000 description 1
210000001732 sebaceous gland Anatomy 0.000 description 1
150000003335 secondary amines Chemical class 0.000 description 1
150000003355 serines Chemical class 0.000 description 1
208000005893 serous cystadenoma Diseases 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
230000008054 signal transmission Effects 0.000 description 1
230000007781 signaling event Effects 0.000 description 1
201000008123 signet ring cell adenocarcinoma Diseases 0.000 description 1
229910052710 silicon Inorganic materials 0.000 description 1
239000010703 silicon Substances 0.000 description 1
150000003376 silicon Chemical class 0.000 description 1
239000002356 single layer Substances 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
208000017520 skin disease Diseases 0.000 description 1
208000000649 small cell carcinoma Diseases 0.000 description 1
210000000813 small intestine Anatomy 0.000 description 1
208000010485 smooth muscle tumor Diseases 0.000 description 1
239000001632 sodium acetate Substances 0.000 description 1
235000017281 sodium acetate Nutrition 0.000 description 1
239000001540 sodium lactate Substances 0.000 description 1
235000011088 sodium lactate Nutrition 0.000 description 1
229940005581 sodium lactate Drugs 0.000 description 1
239000002195 soluble material Substances 0.000 description 1
238000000638 solvent extraction Methods 0.000 description 1
230000009870 specific binding Effects 0.000 description 1
210000000952 spleen Anatomy 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000002269 spontaneous effect Effects 0.000 description 1
239000007921 spray Substances 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
230000004936 stimulating effect Effects 0.000 description 1
201000011549 stomach cancer Diseases 0.000 description 1
208000018556 stomach disease Diseases 0.000 description 1
238000002563 stool test Methods 0.000 description 1
208000028210 stromal sarcoma Diseases 0.000 description 1
238000005556 structure-activity relationship Methods 0.000 description 1
230000004960 subcellular localization Effects 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000007929 subcutaneous injection Substances 0.000 description 1
125000000547 substituted alkyl group Chemical group 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
210000000106 sweat gland Anatomy 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
201000008753 synovium neoplasm Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
210000001138 tear Anatomy 0.000 description 1
230000002123 temporal effect Effects 0.000 description 1
208000001608 teratocarcinoma Diseases 0.000 description 1
150000003505 terpenes Chemical class 0.000 description 1
ISXSCDLOGDJUNJ-UHFFFAOYSA-N tert-butyl prop-2-enoate Chemical compound CC(C)(C)OC(=O)C=C ISXSCDLOGDJUNJ-UHFFFAOYSA-N 0.000 description 1
150000003512 tertiary amines Chemical class 0.000 description 1
201000003120 testicular cancer Diseases 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
229940126585 therapeutic drug Drugs 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
210000000115 thoracic cavity Anatomy 0.000 description 1
229940104230 thymidine Drugs 0.000 description 1
229940113082 thymine Drugs 0.000 description 1
229960002175 thyroglobulin Drugs 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000759 toxicological effect Toxicity 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
230000005030 transcription termination Effects 0.000 description 1
230000001131 transforming effect Effects 0.000 description 1
230000014616 translation Effects 0.000 description 1
230000005945 translocation Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
230000005747 tumor angiogenesis Effects 0.000 description 1
231100000588 tumorigenic Toxicity 0.000 description 1
230000000381 tumorigenic effect Effects 0.000 description 1
238000013060 ultrafiltration and diafiltration Methods 0.000 description 1
210000003606 umbilical vein Anatomy 0.000 description 1
230000036967 uncompetitive effect Effects 0.000 description 1
241000701447 unidentified baculovirus Species 0.000 description 1
241001515965 unidentified phage Species 0.000 description 1
229940035893 uracil Drugs 0.000 description 1
210000003932 urinary bladder Anatomy 0.000 description 1
208000026533 urinary bladder disease Diseases 0.000 description 1
206010046766 uterine cancer Diseases 0.000 description 1
210000001215 vagina Anatomy 0.000 description 1
208000013139 vaginal neoplasm Diseases 0.000 description 1
238000010200 validation analysis Methods 0.000 description 1
201000011531 vascular cancer Diseases 0.000 description 1
206010055031 vascular neoplasm Diseases 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
238000003026 viability measurement method Methods 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
208000006542 von Hippel-Lindau disease Diseases 0.000 description 1
210000003905 vulva Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
229940075420 xanthine Drugs 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Landscapes

Peptides Or Proteins (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Investigating Or Analysing Biological Materials (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA002467433A 2001-11-13 2002-11-13 Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer Abandoned CA2467433A1 (en)

Applications Claiming Priority (37)

Application Number	Priority Date	Filing Date	Title
US35066601P	2001-11-13	2001-11-13
US60/350,666		2001-11-13
US33246401P	2001-11-21	2001-11-21
US60/332,464		2001-11-21
US33439301P	2001-11-29	2001-11-29
US60/334,393		2001-11-29
US33539401P	2001-12-03	2001-12-03
US60/335,394		2001-12-03
US34037601P	2001-12-14	2001-12-14
US60/340,376		2001-12-14
US34721102P	2002-01-08	2002-01-08
US60/347,211		2002-01-08
US34734902P	2002-01-10	2002-01-10
US60/347,349		2002-01-10
US35525002P	2002-02-08	2002-02-08
US60/355,250		2002-02-08
US35671402P	2002-02-13	2002-02-13
US60/356,714		2002-02-13
US35907702P	2002-02-20	2002-02-20
US60/359,077		2002-02-20
US36880902P	2002-03-29	2002-03-29
US60/368,809		2002-03-29
US37011002P	2002-04-04	2002-04-04
US60/370,110		2002-04-04
US37224602P	2002-04-12	2002-04-12
US60/372,246		2002-04-12
US38661402P	2002-06-05	2002-06-05
US60/386,614		2002-06-05
US39683902P	2002-07-16	2002-07-16
US60/396,839		2002-07-16
US39784502P	2002-07-22	2002-07-22
US39777502P	2002-07-22	2002-07-22
US60/397,845		2002-07-22
US60/397,775		2002-07-22
US40945002P	2002-09-09	2002-09-09
US60/409,450		2002-09-09
PCT/US2002/036810 WO2003042661A2 (en)	2001-11-13	2002-11-13	Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer

Publications (1)

Publication Number	Publication Date
CA2467433A1 true CA2467433A1 (en)	2003-05-22

Family

ID=32719847

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA002467433A Abandoned CA2467433A1 (en)	2001-11-13	2002-11-13	Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer

Country Status (4)

Country	Link
EP (1)	EP1497454A2 (de)
JP (1)	JP2005525789A (de)
AU (1)	AU2002357734A1 (de)
CA (1)	CA2467433A1 (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7927597B2 (en)	2001-04-10	2011-04-19	Agensys, Inc.	Methods to inhibit cell growth
WO2004024063A2 (en) *	2002-09-11	2004-03-25	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
ES2364670T3 (es)	2005-02-25	2011-09-12	Oncotherapy Science, Inc.	Vacunas de péptidos para cánceres de pulmón que expresan polipéptidos ttk.
WO2008104803A2 (en) *	2007-02-26	2008-09-04	Oxford Genome Sciences (Uk) Limited	Proteins
WO2009016691A1 (en) *	2007-07-30	2009-02-05	Oncotherapy Science, Inc.	Cancer associated gene ly6k
KR101720760B1 (ko) *	2008-01-25	2017-03-28	오르후스 우니베르시테트	Ｉｇｆｂｐ-4에 대한 ｐａｐｐ-ａ 활성의 선택적 엑소사이트 억제
WO2011115268A1 (ja) *	2010-03-18	2011-09-22	大日本住友製薬株式会社	腫瘍血管新生阻害剤
CN119955936A (zh) *	2025-01-16	2025-05-09	浙江大学	Gabrr1作为肿瘤标记物和靶分子的应用

2002
- 2002-11-13 EP EP02792272A patent/EP1497454A2/de not_active Withdrawn
- 2002-11-13 JP JP2003544445A patent/JP2005525789A/ja active Pending
- 2002-11-13 CA CA002467433A patent/CA2467433A1/en not_active Abandoned
- 2002-11-13 AU AU2002357734A patent/AU2002357734A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP2005525789A (ja)	2005-09-02
EP1497454A2 (de)	2005-01-19
AU2002357734A1 (en)	2003-05-26

Legal Events

Date	Code	Title	Description
2006-11-14	FZDE	Discontinued

Publication	Publication Date	Title
US7435589B2 (en)	2008-10-14	Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US7736853B2 (en)	2010-06-15	Methods of diagnosis of androgen-dependent prostate cancer, prostate cancer undergoing androgen withdrawal, and androgen-independent prostate cancer
US20050181375A1 (en)	2005-08-18	Novel methods of diagnosis of metastatic cancer, compositions and methods of screening for modulators of metastatic cancer
CA2451465A1 (en)	2002-12-27	Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2440703A1 (en)	2002-08-01	Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
CA2459219A1 (en)	2003-03-27	Methods of diagnosis of cancer compositions and methods of screening for modulators of cancer
CA2453098A1 (en)	2003-01-16	Methods of diagnosis of bladder cancer, compositions and methods of screening for modulators of bladder cancer
WO2004048938A2 (en)	2004-06-10	Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators
US20030124579A1 (en)	2003-07-03	Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
CA2425569A1 (en)	2002-04-18	Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
US20070054268A1 (en)	2007-03-08	Methods of diagnosis and prognosis of ovarian cancer
US20030235820A1 (en)	2003-12-25	Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
CA2444691A1 (en)	2002-10-31	Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
US20030232350A1 (en)	2003-12-18	Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20040029114A1 (en)	2004-02-12	Methods of diagnosis of breast cancer, compositions and methods of screening for modulators of breast cancer
US20100297152A1 (en)	2010-11-25	Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer
US20030228570A1 (en)	2003-12-11	Methods of diagnosis of Hepatitis C infection, compositions and methods of screening for modulators of Hepatitis C infection
CA2438030A1 (en)	2002-10-10	Methods of diagnosis of angiogenesis, compositions and methods of screening for angiogenesis modulators
US20060269921A1 (en)	2006-11-30	Methods of diagnosis and prognosis of pancreatic cancer
US20070178458A1 (en)	2007-08-02	Methods of diagnosis and prognosis of ovarian cancer II
WO2004073657A2 (en)	2004-09-02	Methods of diagnosis of cancer and other diseases, composition and methods of screening for modulators of cancer and other diseases
CA2381699A1 (en)	2001-02-15	Novel methods of diagnosis of angiogenesis compostions and methods of screening for angiogenesis modulators
US20070059748A1 (en)	2007-03-15	Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
CA2467433A1 (en)	2003-05-22	Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US20020068036A1 (en)	2002-06-06	Novel methods of diagnosis of prostate cancer and/or breast cancer, compositions, and methods of screening for prostate cancer and /or breast cancer modulators